|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rifaximin vs conventional oral therapy for hepatic encephalopathy:A meta-analysis显示文摘AIM: To characterize the efficacy of rifaximin in the management of hepatic encephalopathy (HE) as several randomized controlled studies have shown contradictory results on its effectiveness in comparison to other oral agents. METHODS: We performed a systematic review and random effects meta-analysis of all eligible trials identifi ed through electronic and manual searches. Twelve randomized controlled trials met the inclusion criteria with a total of 565 patients. RESULTS: The clinical effectiveness of rifaximin was equivalent to disaccharides or other oral antibiotics[odds ratio (OR) 0.96; 95% CI: 0.94-4.08] but with a better safety profi le (OR 0.27; 95% CI: 0.12-0.59). At the completion of treatment protocols, patients receiving rifaximin showed lower serum ammonia levels [weighted mean difference (WMD) = -10.65; 95% CI: -23.4-2.1; P = 0.10], better mental status (WMD = -0.24; 95% CI: -0.57-0.08; P = 0.15) and less asterixis (WMD -0.1; 95% CI -0.26-0.07; P = 0.25) without reaching statistical signifi cance. On the other hand, other psychometric outcomes such as electroencephalographic response and grades of portosystemic encephalopathy were superior in patients treated with rifaximin in comparison to the control group (WMD = 0.21, 95% CI: -0.33-0.09, P = 0.0004; and WMD = -2.33, 95% CI: -2.68-1.98, P = 0.00001, respectively). Subgroup and sensitivity analysis did not show any signifi cant difference in the above fi ndings. CONCLUSION: Rifaximin appears to be at least as effective as other conventional oral agents for the treatment of HE with a better safety profi le. | Karim M Eltawil Marie Laryea Kevork Peltekian Michele Molinari | 2012 | World Journal of Gastroenterology2012，18，8： | 9 |
| 2 | Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population显示文摘 | Morris Sherman Kevork M. Peltekian Cindy Lee | 1995 | Hepatology1995，，2： | 6 |
| 3 | Evidence-Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature显示文摘 | Murad Aljiffry Alhawsawi Abdulelah Mark Walsh Kevork Peltekian Ian Alwayn Michele Molinari | 2008 | Journal of the American College of Surgeons2008，，1： | 3 |
| 4 | Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and threedimensional in vitro models显示文摘BACKGROUND Colorectal cancer(CRC) is the second leading cause of cancer-related mortality.Cancer stem cells(CSCs) in CRC, which are spared by many chemotherapeutics,have tumorigenic capacity and are believed to be the reason behind cancer relapse. So far, there have been no effective drugs to target colon CSCs. Diiminoquinone(DIQ) has shown promising effects on targeting colon cancer.However, there is limited research on the effects of DIQ on eradicating CSCs in CRC.AIM To investigate the anticancer potential of DIQ on colon CSCs in two-dimensional(2D) and three-dimensional(3D) models using colonospheres and patient-derived organoids.METHODS Various 2D methods have been used to assess the effect and the mechanism of DIQ on HCT116and HT29 cell lines including cell proliferation and viability assays, migration and invasion assays,immunofluorescence staining, and flow cytometry. The potency of DIQ was also assessed in 3D culture using the sphere formation assay and colon cancer patient-derived organoid model.RESULTS Our results showed that DIQ significantly inhibited cell proliferation, migration, and invasion in HCT116 and HT29 cell lines. DIQ treatment induced apoptosis along with an accumulation of HCT116 and HT29 cancer cells in the sub-G1 region and an increase in reactive oxygen species in both CRC cell lines. DIQ reduced sphere-forming and self-renewal ability of colon cancer HCT116and HT29 stem/progenitor cells at sub-toxic doses of 1 μmol/L. Mechanistically, DIQ targets CSCs by downregulating the main components of stem cell-related-catenin, AKT, and ERK oncogenic signaling pathways. Potently, DIQ displayed a highly significant decrease in both the count and the size of the organoids derived from colon cancer patients as compared to control and 5-fluorouracil conditions.CONCLUSION This study is the first documentation of the molecular mechanism of the novel anticancer therapeutic DIQ via targeting CSC, a promising compound that needs further investigation. | Alissar Monzer Kevork Wakimian Farah Ballout Samar Al Bitar Amani Yehya Mariam Kanso Nour Saheb Ayman Tawil Samer Doughan Maher Hussein Deborah Mukherji Walid Faraj Hala Gali-Muhtasib Wassim Abou-Kheir | 2022 | World Journal of Gastroenterology2022，28，33： | 1 |
| 5 | Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population显示文摘 | Morris Sherman Kevork M. Peltekian Cindy Lee | 1995 | Hepatology1995，，2： | 1 |
| 6 | Diabetes melJitis: risk (actoy foradvanced liver disease显示文摘 | Ferhan S Q Lindsay C Kevork M | 2011 | CMAJ2011，183，5： | 1 |
| 7 | The G691S ret polymor-phism increases glial cell line derived neurotrophic factorinduced pancreatic cancer celllnvasio by amplifying mito-gen activated protein kinase signaling显示文摘 | Irozumi S Yuji 0 Kevork K | 2005 | Cancer Res2005，65，11： | 1 |
| 8 | Development of a Process to Produce Lead Oxide From Imperial Smelting Furnace Copper/Lead Dross 显示文摘 | Kevork A Chouzadjian Stephen J Roden Gary J Davis | 1991 | Hy- drometallurgy1991，26，3： | 1 |
| 9 | The clinical features of the piriformis syndrome:a systematic review显示文摘 | Kevork Hopayian Fujian Song Ricardo Riera | 2010 | Euro-pean Spine Journal2010，19，12： | 1 |
| 10 | Development of a process to produce lead oxide from Imperial smelting furnace copper/lead dross 显示文摘 | Kevork A Chouzadjian Stephen J Roden Gary J Davis | 1991 | H ydrometallurgy1991，26，3： | 1 |
| 11 | Distal Pancreatectomy: Incidence of Postoperative Diabetes显示文摘 | Jonathan King Kevork Kazanjian J. Matsumoto Howard A. Reber Michael W. Yeh O. Joe Hines Guido Eibl | 2008 | Journal of Gastrointestinal Surgery2008，，9： | 1 |
| 12 | Diabetes mellitis: risk factoy for advanced liver disease显示文摘 | ethan SQ Linclsay C Kevork M | 2011 | CMAJ2011，183，： | 1 |
| 13 | An Evidence-Based Manual for Abdominal Paracentesis显示文摘 | Angela McGibbon Grant I. Chen Kevork M. Peltekian Sander Veldhuyzen van Zanten | 2007 | Digestive Diseases and Sciences2007，，12： | 1 |
| 14 | Drug resistance in metastatic castration-resistant prostate cancer:an update on the status quo显示文摘Prostate cancer(PCa)is a leading cause of cancer-related morbidity and mortality in men globally.Despite improvements in the diagnosis and treatment of PCa,a significant proportion of patients with high-risk localized disease and all patients with advanced disease at diagnosis will experience progression to metastatic castration-resistant prostate cancer(mCRPC).Multiple drugs are now approved as the standard of care treatments for patients with mCRPC that have been shown to prolong survival.Although the majority of patients will respond initially,primary and secondary resistance to these therapies make mCRPC an incurable disease.Several molecular mechanisms underlie the development of mCRPC,with the androgen receptor(AR)axis being the main driver as well as the key drug target.Understanding resistance mechanisms is crucial for discovering novel therapeutic strategies to delay or reverse the progression of the disease.In this review,we address the diverse mechanisms of drug resistance in mCRPC.In addition,we shed light on emerging targeted therapies currently being tested in clinical trials with promising potential to overcome mCRPC-drug resistance. | Amani Yehya Fatima Ghamlouche Amin Zahwe Yousef Zeid Kevork Wakimian Deborah Mukherji Wassim Abou-Kheir | 2022 | Cancer Drug Resistance2022，5，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员